Skip to content
DataLookout
Menu

NCT07920861

A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight Subjects; and Pharmacokinetics at Different Subcutaneous Injection Sites at the Same Dose

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Adverse events
Timeframe: through study completion
Cmax
Timeframe: From pre-dosing to 140 days post-dosing
AUCinf
Timeframe: From pre-dosing to 140 days post-dosing

Secondary (9)

AUC
Cmax
Tmax
Vz
CL
Show 4 moreShow less
t1/2
Adverse events
ADA
Nab

Arms and interventions

PART1: Group 1,75mgExperimental

single-dose, SC, HB0017 75 mg or placebo

PART1: Group 2, 150mgExperimental

single-dose, SC, HB0017 150 mg or placebo

PART1: Group 3, 300mgExperimental

single-dose, SC, HB0017 300 mg or placebo

PART2: Group 4, 150mg, domenExperimental

single-dose, SC at domen, HB0017 150 mg

PART2: Group 5, 150mg, upper armsExperimental

single-dose, SC at upper arms, HB0017 150 mg

PART2: Group 6, 150mg, thihgsExperimental

single-dose, SC at thighs, HB0017 150 mg

PART2: Group 7, 300mg, domenExperimental

single-dose, SC at domen, HB0017 300 mg

PART2: Group 8, 300mg, upper armsExperimental

single-dose, SC at upper arms, HB0017 300 mg

PART2: Group 9, 300mg, thighsExperimental

single-dose, SC at thighs, HB0017 300 mg

Biologicals: HB0017 Injection

Other: HB0017 Placebo

Sites

1 site in 1 country

  • First People's Hospital of HangzhouHangzhou, Zhejiang, China